Jia Ee Chia, Song Peng Ang, Muhammed Haris Usman, Chayakrit Krittanawong, Debabrata Mukherjee
{"title":"Trends, Characteristics and Outcomes in Breast Cancer Survivors With STEMI.","authors":"Jia Ee Chia, Song Peng Ang, Muhammed Haris Usman, Chayakrit Krittanawong, Debabrata Mukherjee","doi":"10.1177/00033197241308045","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer is the most common malignancy among women. While advances in detection and treatment have improved survival, breast cancer survivors face an increased risk of cardiovascular disease. However, limited data exist on cardiac outcomes after ST-elevation myocardial infarction (STEMI) in this population. This retrospective cohort study analyzed the National Inpatient Sample (NIS) database (2016-2021). Adult women hospitalized with STEMI were categorized as breast cancer survivors or without a history of breast cancer. The primary outcome was in-hospital mortality, with multivariable logistic regression used to adjust for confounders. A total of 369,070 adult females were included (breast cancer survivors, <i>n</i> = 13,890; without breast cancer, <i>n</i> = 355,180). Breast cancer survivors were older with more cardiovascular comorbidities. After adjustment, breast cancer survivors had lower odds of in-hospital mortality (adjusted odds ratio [aOR] 0.82, 95% CI 0.72-0.93), cardiogenic shock (aOR 0.88, 95% CI 0.77-0.99), and acute kidney injury (aOR 0.85, 95% CI 0.76-0.95). Breast cancer survivors hospitalized for STEMI had lower in-hospital mortality and complications, compared with those without breast cancer. These hypothesis-generating findings suggest that advances in oncology and cardiovascular care may contribute to improved outcomes.</p>","PeriodicalId":8264,"journal":{"name":"Angiology","volume":" ","pages":"33197241308045"},"PeriodicalIF":2.6000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Angiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00033197241308045","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Breast cancer is the most common malignancy among women. While advances in detection and treatment have improved survival, breast cancer survivors face an increased risk of cardiovascular disease. However, limited data exist on cardiac outcomes after ST-elevation myocardial infarction (STEMI) in this population. This retrospective cohort study analyzed the National Inpatient Sample (NIS) database (2016-2021). Adult women hospitalized with STEMI were categorized as breast cancer survivors or without a history of breast cancer. The primary outcome was in-hospital mortality, with multivariable logistic regression used to adjust for confounders. A total of 369,070 adult females were included (breast cancer survivors, n = 13,890; without breast cancer, n = 355,180). Breast cancer survivors were older with more cardiovascular comorbidities. After adjustment, breast cancer survivors had lower odds of in-hospital mortality (adjusted odds ratio [aOR] 0.82, 95% CI 0.72-0.93), cardiogenic shock (aOR 0.88, 95% CI 0.77-0.99), and acute kidney injury (aOR 0.85, 95% CI 0.76-0.95). Breast cancer survivors hospitalized for STEMI had lower in-hospital mortality and complications, compared with those without breast cancer. These hypothesis-generating findings suggest that advances in oncology and cardiovascular care may contribute to improved outcomes.
期刊介绍:
A presentation of original, peer-reviewed original articles, review and case reports relative to all phases of all vascular diseases, Angiology (ANG) offers more than a typical cardiology journal. With approximately 1000 pages per year covering diagnostic methods, therapeutic approaches, and clinical and laboratory research, ANG is among the most informative publications in the field of peripheral vascular and cardiovascular diseases. This journal is a member of the Committee on Publication Ethics (COPE). Average time from submission to first decision: 13 days